Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Lung Cancer Oncologists (US)(?)

Council Members in this Study Group: 85

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
Taral Patel, MD, Oncologist, Mid Ohio Oncology Hematology Inc.Taral Patel, MD
Oncologist
Mid Ohio Oncology Hematology Inc.

Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...


8 recent news post(s)
Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CCKenneth Algazy, MD
Clinical Professor of Medicine
University of Pennsylvania School of Medicine - CC

Kenneth Algazy, MD, is a Clinical Professor of Medicine at University of Pennsylvania School of Medicine. He is also a Section Chief in the Division of Hematology and Oncology at Philadelphia VA Medical Center. Dr. Algazy is involved in clinical trials in lung cancer, and interested in demographics...


341 recent news post(s)

Related Study Groups

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Novo Nordisk: Good try but recombinant activated factor VII did not reach its goal in hemorrhagic stoke | 05-15-2008
Analysis of: Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage | content.nejm.org
Author: Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC

"In summary, rFVIIa reduced hematoma growth but did not reduce the rate of death or severe disability after intracerebral hemorrhage."

Can NOV-002 from Novelos Therapeutics Break into Therapy for Breast, Lung,or Ovarian Cancers? | 05-14-2008
Analysis of: Novelos Therapeutics announces positive results in ongoing phase 2 neoadjuvant breast cancer trial as Musc Hollings Cancer Center | www.pipelinereview.com
Author: GLG Expert Contributor

The positive interim results released by Novelos Therapeutics about its chemoprotectant / chemopotentiator NOV-002 were not very meaty: Divining the true implications of pathologic CRs in neo-adjuvant breast cancer can be tricky.  Plus, this was a open label, phase II study, and the number of patients reported...

GSK: Gutsy but logical clinical trial of Tykerb v Herceptin (Genentech) | 05-13-2008
Analysis of: Glaxo Tests Tykerb vs Herceptin in Early Cancer | www.therapeuticsdaily.com
Author: Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC

Glaxo is trying to move Tykerb ahead of Herceptin in a first line/neoajuvant/adjuvant setting in Her2Neu + Breast cancer.

ImClone: Does Morgan Stanley (MS) know something we don't?? | 05-12-2008
Analysis of: US Drug Stocks Edge Higher, But ImClone Falls On Downgrade | news.ino.com
Author: Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC

Erbitux was touted to have a positive study in Non Small Cell Lung Cancer (NSCLCA) but all they said was that is was a positive study. No further info at that time but an executive bought a block of stock a few days before the announcement which led to an inevitable rise in the stock price! Does this...

BioSimilar G-CSF Might be Coming: How Will it Stack up to Neupogen? | 05-12-2008
Analysis of: Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market | www.pipelinereview.com
Author: GLG Expert Contributor

Now that liquid Leukine (GM-CSF) has been withdrawn by Bayer, Amgen commands the North American G-CSF market with its Neupogen and Neulasta.  However, Indian manufacturer INTAS Biopharmaceuticals Ltd. (IBPL) has been treating patients with a biosimilar G-CSF called Neukine since 2004.  And...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Academic Institution*
  • Government/Military Hospital or Clinic
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Partner
  • Owner
  • Physician - Division Head

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics